These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31875931)

  • 21. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
    Kumagai Y; Sakaki M; Furihata K; Ito T; Inoue K; Yoshida T; Matsumoto S; Furuno K; Hagino A
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):25-35. PubMed ID: 31760530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
    Tanaka A; Taguchi I; Hisauchi I; Yoshida H; Shimabukuro M; Hongo H; Ishikawa T; Kadokami T; Yagi S; Sata M; Node K;
    Eur J Med Res; 2023 Jul; 28(1):238. PubMed ID: 37461063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacological properties and clinical efficacy of dotinurad (URECE
    Taniguchi T; Ashizawa N
    Nihon Yakurigaku Zasshi; 2020; 155(6):426-434. PubMed ID: 33132262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in Urinary Uric Acid Concentration after Dotinurad Administration to Patients with Hyperuricemia: A Post Hoc Analysis of Two Clinical Trials in Japan.
    Takahashi T; Sasaki M; Shimizu T; Yamaguchi S
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):87-95. PubMed ID: 37559414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
    Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
    J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Lee HA; Yu KS; Park SI; Yoon S; Onohara M; Ahn Y; Lee H
    Rheumatology (Oxford); 2019 Nov; 58(11):1976-1984. PubMed ID: 31056705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
    Hosoya T; Ishikawa T; Ogawa Y; Sakamoto R; Ohashi T
    Clin Drug Investig; 2018 Dec; 38(12):1135-1143. PubMed ID: 30219951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.
    Song D; Zhao X; Wang F; Wang G
    Eur J Pharmacol; 2021 Sep; 907():174291. PubMed ID: 34216576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
    Hou Z; Ma A; Mao J; Song D; Zhao X
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
    Ishikawa T; Maeda T; Hashimoto T; Nakagawa T; Ichikawa K; Sato Y; Kanno Y
    Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

  • 40. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.